Skip to main content

Jubilant Pharmova Ltd

Stage 2 · Advancing · week 1Setup 6.4 ★ FairStrong +7.2

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. More about the company

₹931.9
-0.03% today
₹14,760 Cr · Mid cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts
Loading price chart…
vs 52W High
-21.1%
₹807.7 lo₹1,181.2 hi
21.1% below 52W high — deeper pullback
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 1
1w13w26w
Week 1 — fresh breakout, verify structure
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
-2.4%
200 DMA: ₹954.8 · sloping down
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.39x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
↑ ⇈
Accelerating · MA20 +3.9% vs MA50 +1.5% / 10d
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-6.6%
3M
-3.3%
6M
+6.2%
YTD
-13.9%
1Y
-16.3%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #65 of 74 Stage 2 stocks in Health Care by RS. Lagging sector peers.
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #51 of 58 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 16w
S2 53w
S4 16w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 16w → S3 6w → S2 53w → S3 11w → S4 11w → S1 5w → S2 8w → S3 10w → S2 5w → S3 5w → S4 16w → S1 12w → S4 7w → S1 1w → S2 1w current
Total tracked: 167 weeks across 15 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-10-05
3 appearances in last 60 days. First seen: 2025-07-02.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 1 · Vol 0.39x
2026-10-08S2
Wk 1 · Vol 1.33x
2026-10-07S2
Wk 1 · Vol 0.22x
2026-10-06S2
Wk 1 · Vol 0.56x
2026-10-05S21→2
Wk 1 · Vol 0.66x
2026-10-01S1
Wk 1 · Vol 1.10x
2026-09-30S1
Wk 1 · Vol 1.55x
2026-09-29S1
Wk 1 · Vol 3.82x
2026-09-28S1
Wk 1 · Vol 0.34x
2026-09-25S14→1
Wk 1 · Vol 0.56x
2026-09-24S4
Wk 7 · Vol 0.39x
2026-09-23S4
Wk 7 · Vol 0.47x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹956.2
200 DMA
₹954.8
52W High
₹1,181.2
52W Low
₹807.7
5D Low
₹931.9
Resistance levels (recent highs)
20d High
₹1,072
60d High
₹1,072
120d High
₹1,072
250d High
₹1,181.2
Next resistance
+15.0%
to 20d High
P/E (TTM)
39.5
Forward 19.5
Earnings Growth (YoY)
-22.4%
Revenue +18.7%
ROE
+6.0%
Profit margin +4.8%
Dividend Yield
0.51%
P/B 2.4
About this companyHealth Care· Pharmaceuticals

Jubilant Pharmova Limited operates as an integrated pharmaceutical company in India, the Americas, Europe, and internationally. It operates through six segments: Radiopharma; Allergy Immunotherapy; Contract Development and Manufacturing Organisation - Sterile Injectables; Generics; Contract Research Development and Manufacturing Organisation; and Proprietary Novel Drugs. The Radiopharma segment offers radiopharmaceuticals products, which are used in the diagnosis and treatment of various diseases, including pulmonary embolism, cancer, coronary artery disease, and others. Its Allergy Immunotherapy segment provides specialised diagnostic devices for skin testing, as well as venom and allergy immunotherapy products. The Contract Development and Manufacturing Organisation - Sterile Injectables segment offers contract manufacturing services for sterile fill and finish injectables, liquids, ointments, creams, and ampoules. Its Generics segment engages in the development, manufacturing, distribution, sale, and marketing of generic formulations for therapeutic areas comprising cardiovascular system, central nervous system, gastrointestinal, antibiotics, and multispecialty. The Contract Research Development and Manufacturing Organisation segment offers drug discovery services and active pharmaceutical ingredients. The Proprietary Novel Drugs segment provides patient-focused biopharmaceutical services to address unmet medical needs in oncology and autoimmune diseases. The company serves pharmaceutical, biotech, group purchasing organisations, allergists, and hospitals sectors. It sells its products through a network of dealers and distributors. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is based in Noida, India.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.